In the last decade, the pharmacological management of T2D has been improved by the discovery of new insulin sensitiser molecules such as thiazolidinediones (TZDs), also called ‘glitazones’, which able to ameliorate insulin sensitivity (HbA1c reduction of −2.0 ± 0.4%) [112] and pancreatic β-cells function by stimulating the activity of PPARγ, a critical target of the regulation of energy homeostasis. Here, INS is linked to type 2 diabetes mellitus.